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The immune response by mature peripheral T cells requires the recognition of
antigens presented in the context of self-MHC molecules (1, 2). After antigen pre-
sentationby class I or class II MHC molecules, specific antigen recognition involves
the TCRwiththeaid ofeither CD8 orCD4 molecules, respectively (3). These same
components, class I and class II self-MHC, TCR, and CD4, are present and have
been implicatedin the processofintrathymicT celldevelopment and selection, positive
and/or negative (4-25), but the function of the CD8 molecule during any ofthese
developmental events is largely unknown.
Early reports demonstrated that MHC molecules play a crucial role during T
cell development. In vivo studies in neonatal mice showed that CD4* T cells failed
to develop in anti-class II-suppressed mice (4), whereas CD8+ T cells failed to de-
velop in anti-class I-suppressed mice (5). Thus, differentiation ofprecursor T cells
into mature T cells involvespositive selection onthe basis oftheir MHC specificity.
TCRMHC interactionshavebeen postulated tomediate the recognition events neces-
sary for positive selection (6-9). Findings that support this concept are many and
varied. Studies in F, neonatal mice (Ia-k/Ia-b) established that the appearance of
Th cell populations restricted by either Ia-kor Ia-b is specifically inhibited by treat-
ments with anti-Ia-k or anti-Ia-b antibodies, respectively (10). Other experimental
support for this notion was provided by studies in transgenic mice (11, 12), and by
studies in anti-class I mAb-treated mice (13, 14) or antiTCRtreated mice (15).
TCRMHC interactions are not the only ones that are crucial to the process of
positiveselection. Recently, weshowed that other interactions, such as thosebetween
MHC and accessory molecules, are essential as well (16). These findings demon-
strated that anti-CD4-suppressed mice failed to generate CD4+ T cells, suggesting
that CD4 molecules are involved in the positive selection ofthe T cell repertoire.
The concept that MHC, TCR, and CD4 are involved during positive selection
alsoextendsto theirparticipation in negative selection. TCRMHC interactions are
clearly involved inthe process ofnegative selection. Avariety ofexperimental systems
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demonstrated that tolerance induction, at least for certain self-class I and class II
or class II-associated antigens expressed in the thymus, occurs through clonal dele-
tion of T cells with self-reactive TCRs (18, 22). The idea that CD4 participates in
negative selection ofclass II-reactive T cells is supported by the recent observation
that blocking of CD4 allowed self-reactive TCR+ T cells to escape clonal deletion
at the CD4+/CD8+ stage, thus permitting the generation of CD8+ T cells that other-
wise would not have survived (23, 24). No such correlates have been established for
the involvement of CD8 during negative selection; however, this problem is com-
pounded by the lack of any defined TCR V# region that is negatively selected on
class I MHC. Thus, the tools for such an analysis are not yet available. Nonetheless,
from studies with TCRtransgenic mice expressing a class I-restricted TCR, it ap-
pears that CD8 plays a similar role in deletion of class I-restricted T cells as CD4
does for class II-restricted T cells: the deletion spares cells with low CD8 expression,
while those with high levels are deleted (25).
This paper addresses the function of the CD8 molecule during the positive selec-
tion of CD4-/CD8 + T cells. To this end, the effects of blocking CD8 with an anti-
CD8 mAb during T cell development were analyzed in vivo. The in vivo experi-
ments involved the treatment of pregnant mice and their progeny for up to 2 wk
of age with anti-CD8 mAb. The results from these studies indicate that treatments
with intact or divalent, F(ab')2, anti-CD8 mAbs do not deplete, but rather prevent
the generation of CD4-/CD8+ T cells. CD8 molecules are therefore involved in the
positive selection of the T cell repertoire.
Materials and Methods
Mice.
￿
Timed pregnant BALB/c and C3H x BALB/c mice were obtained from the Na-
tional Cancer Institute (Frederick, MD). The day of a vaginal plug was designated as day
0 of embryonic development.
Antibodiesand Treatments.
￿
The anti-CD8.2 mAb, 2.43 (26), was purified from nude mice
ascites by ammonium sulfate precipitation and sephadex column size separation. Concen-
trated antibodies were dialyzed against PBS, filter sterilized, and the concentration of the
mAb was determined by spectrophotometric absorbance. The F(ab')2 fragments were pre-
pared as previously described (27). The F(aU)2 fragment preparations ofanti-CD8 mAb were
analyzed by SDS-PAGE and shown to contain no detectable intact anti-CD8 mAb. Anti-
CD8 activity ofthe fragments was demonstrated by their ability to block staining with FITC-
or biotin-conjugated anti-CD8 mAb. Absence of intact anti-CD8 mAb was further demon-
strated by the failure of the F(ab')2 fragments to cause depletion ofCD4-/CD8' T cells when
injected into adult mice, in an acute regimen leading to depletion when intact anti-CD8 mAb
is used (data not shown).
In Vioo Treatment with Anti-CD8 mAb.
￿
Pregnant mice were treated from day 16-17 ofpreg-
nancy with a daily dose of 0.5 mg of 2.43 mAb, i.p., and treatment was continued on their
neonatal offspring at a daily dose of 0.2 mg of 2.43 mAb, i.p., for up to 2 wk. 1 d aftertreat-
ment termination, thymocyte suspensions were analyzed by FACS. Controls consisted ofsa-
line injections of equal volume and regimen. For single-positive (CD4' and/or CD8') T cell
enrichment, control and treated mice were injected with hydrocortisone acetate (HC)' (0.2
mg, i.p.) 2 d before analysis (28). Before FACS, nonviable cells were removed by density gra-
dient separation (Lympholyte-M; Cedar Lane, Ontario, Canada). The viability of cell sus-
pensions was determined by trypan blue exclusion.
Fluorescence Staining(FACS).
￿
Cell suspensions were prepared in HBSS (without phenol red)
containing 1% BSA and 0.1% sodium azide (FACS buffer). Cells (106/100 JAI buffer) were
incubated on ice for 30 min with 10 ,.l of the appropriate antibody, and washed twice after
each incubation. Control staining of cells, either stained with irrelevant antibody or withZUNIGA-PFLLJCKER ET AL .
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second-step antibody alone, were used to obtain background fluorescence values . The samples
were analyzed on a FACS 440 (Becton Dickinson & Co., Mountain View, CA) interfaced
to a PDP 11/24 computer, as previously described (4) . Data were collected on 50,000 cells
and are shown as contour diagrams, with a three-decade log scale of green fluorescence on
the x-axis, and a three-decade log scale of red fluorescence on they-axis . Reagents used for
direct staining were FITC- or biotin-conjugated anti- :TCRa/0 (29), CD3 (30), CD4(31),
CD5 (32), CD8 (32), CD8.2 (26), and CD8-a (Lyt-3) (33) . For indirect staining, FITC-
conjugated goat anti-rat IgG was used as described (34) .
Results and Discussion
In Vivo Anti-CD8 Treatment.
￿
To test the possible contribution of C138-ligand(class
I MHC) (3) interactions duringT cell development, the effect of anti-CD8 treat-
ment in vivo was analyzed . Thymocytes from BALB/c mice that have been treated
with anti-CD8 mAb pre- and postnatally became saturated with the specific mAb,
and, most importantly, the majority of CD8-expressing cells remained present
(data not shown), suggesting that CD8+ thymocytes had not undergone cytotoxic
depletion .
To addressthephenotypic changes induced by the blocking of theCD8 molecule,
awide spectrum of cell surface markers were analyzed . First, staining forCD8 and
CD4 was performed. Fig . 1 a shows that in the anti-CD8 mAb-treated thymi, the
staining with directly labeledGD8FITC is blocked, demonstrating total saturation
of the CD8 molecule.
TheCD8 molecule is composed oftwo chains, an a chain (Lyt-2) and a (3 chain
(Lyt-3) (33, 35) . Ourtreatments were directed to theachain ; thus, wecan visualize
the presence ofCD8+ T cells by staining for the CD8 (3 chain . The antibody used
for anti-CD8 treatment (2.43, anti-CD8.2, previously known as Lyt-2 .2) (26) does
not crossblock the staining for CD8-(3 (53-5.8, anti-Lyt-3) (33) (data not shown) .
Fig . 1 b shows that staining for CD8-/3 allows for the visualization of CD4+/CD8+
(double-positive) T cells in anti-CD8-treated mice, albeit the CD8 molecules are
downmodulated, and also suggests an absence of CD4-/CD8+ T cells .
FIGURE 1 .
￿
Two-parameter flow cytometry
analysis of cell surface expression of (a)
CD4vs . CD8(Lyt-2) or(b)CD4 vs .CD8-
0(Lyt-3)on thymocytes from controland
anti-CD8-treated groups . Timed pregnant
BALB/c mice and their offspring were
treated with 2.43mAb. Intraperitoneal in-
jections of 0.5 mg were given daily from
day 16 ofpregnancyandcontinued at 0.2
mg for 12dafter birth. Thymocytes were
analyzed on day 13 after birth .430 CD8 DURING POSITIVE SELECTION OF CD4-/CD8+ T CELLS
To further analyze the presence ofCD4+/CD8 + and absence of CD4-/CD8+ T
cells in the anti-CD8-treated thymi, we analyzed the level of CD3 expression on
CD4+ and CD4- T cells. Fig . 2 a shows that control thymi contain CD4+ T cells,
which are CD3- (corresponding to CD4+/CD8+/CD3-), CD3 dull (CD4+/CD8+/
CD3+), andCD3 bright (CD4+/CD8-). These thymi also containCD4-T cells that
are CD3- (CD4-/CD8-) and CD3+ (CD4-/CD8+, perhaps also some CD4-/
CD8- ) . Clearly, after anti-CD8 treatment the only population that is altered is the
CD4- T cells that are CD3+ (CD4-/CD8+) . No significant changes are observed
in the CD4+/CD8-/CD3+ population, nor in the expression ofCD3 (dull) on the
CD4+/CD8+Tcells . The first observation is at odds with earlier work in which anti-
CD8 prevented the generation of CD4+ T cells (36) . However, mixed allogeneic
tetraparental chimeras were used in those studies, such that graft-vs.-graft reactions,
rather than blocking of development, mayhave caused this subset's elimination . The
second observation shows that contrary to the effects ofanti-CD4 on CD3 expres-
sion after pre- or postnatal engagement (16, 34), anti-CD8 has no effects on the ex-
pression ofCD3 on the dull double-positive population . This observation has now
been confirmed with saturating doses of three different anti-CD8 mAbs (data not
shown) .
Next, by using theCD5 marker (Ly-1), we could clearly visualize, in the control
thymus, a population ofCD5+/CD4- T cells (corresponding to CD8+) (37) (Fig.
2 b) ; this population was absent afterthe anti-CD8 treatment, while theotherpopu-
lations remained unchanged .
Taken together, these findings demonstrate that treatment with anti-CD8 mAb
affects only the presence oftheCD3+/CD4-/CD5+/CD8 + T cells, and has no effect
on the generation of the other major thymic phenotypes (Figs . 1 and 2) . Most
significantly, double-positiveT cellsdevelopednormally in the treated groups ; thus,
these results argue that the absence of CD4-/CD8 + T cells is not due to a deple-
tion of CD4+/CD8+ precursor T cells .
FIGURE 2 . Two-parameter flow cytom-
etry analysis of cell surface expression of
(a) CD4 vs . CD3 or (b) CD5 vs . CD4 on
thymocytes from control and anti-CD8-
treated groups . Timed pregnant BALB/c
mice and their offspring were treated with
2 .43mAb. Intraperitoneal injections of0 .5
mg were given daily from day 16 of preg-
nancy and continued at 0 .2 mg for 12 d
after birth . Thymocytes were analyzed on
day 13 after birth .ZUNIGA-PFLOCKER ET AL . 431
To better visualize the presence or absence of the CD8+ T cell population, con-
trol and treated groups were subjected to HC treatment 2 d before analysis (28) .
HC enriches for single-positive mature T cells (Fig. 3 a; reference 38) . Again, anti-
CD8-treated thymi showed no staining with directly labeled CD8 FITC (Fig. 3 a) .
This lack of positive staining was not due to saturation and/or blocking oftheCD8
molecule, but rather due to a complete absence of theCD8+ T cell population, as
shown by the lack of CD8-/3+ T cells as well (Fig . 3 b) .
Finally, we examined the mature thymocytes (HC thymus) for the expression of
CD5 and TCR on the CD4+ or CD4- population . This allows for the visualiza-
tion of the two main populations in an indirect fashion (Fig . 4 a), so as to avoid
FIGURE 3 . Two-parameter flow cytom-
etry analysis of cell surface expression of
(a) CD4 vs . CD8 or (b) CD4 vs . CD8-0
on thymocytes from HC-treated control
and anti-CD8-treated groups . Timed preg-
nant BALB/c mice and theiroffspring were
treated with 2.43 mAb . Intraperitoneal in-
jections of 0.5 mg were given daily from
day 16 of pregnancy and continued at 0.2
mg for 12 d after birth . Thymocytes were
analyzed on day 13 after birth . Control and
anti-CD8-treated mice were injected with
0.2 mg, i .p ., of HC 2 d before analysis .
FIGURE 4 .
￿
Two-parameter flow cytom-
etry analysis of cell surface expression of
(a)CD5 vs . CD4 or (b)CD4 vs .TCIia/(3
on thymocytes from HC-treated control
and anti-CD8-treated groups . Timed preg-
nant BALB/c mice and their offspring were
treated with 2.43 mAb . Intraperitoneal in-
jections of 0.5 mg were given daily from
day 16 of pregnancy and continued at 0.2
mg for 12 d after birth . Thymocytes were
analyzed on day 13 after birth . Control and
anti-CD8-treated mice were injected with
0.2 mg, i.p ., of HC 2 d before analysis .432
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any problems with antibody blocking. In the control thymi, CD5+/CD4- cor-
respond to CD8+ T cells, while CD5+/CD4+ correspond to CD4+ T cells (37). Fig.
5 a shows that the CD8+ Tcell population (CD5+/CD4-) is completely absent in
the anti-CD8-treated mice. The failure to generate the CD8+ T cells can also be
demonstrated by examiningtheexpression ofTCR-odf on HC thymi. The control
thymi contain two well-defined populations ofTCR+ (bright) cells (Fig. 4 b), one
in the CD4+ subset and one in the CD4- subset (CD8+). The CD4-/TCR+ (CD8+)
Tcells are clearly absent in the treated group, thus, confirming the failure to generate
such T cells when the CD8 molecule is blocked during T cell development.
In Vivo Anti-CD8 F(ab')z Fragment Treatment.
￿
The absence ofCD4-/CD8+ T cells
after anti-CD8 treatment suggests a role for the CD8 molecule during the positive
selection ofCD8+ T cells. Selective removal ofCD4-/CD8+ T cells by the anti-CD8
mAb seems an unlikely explanation for the present results, since CD4+/CD8+ cells
bind the mAb equally well, yet their generation was not affected (Figs. 1 and 2).
Nonetheless, we examined the mechanisms by which the anti-CD8 might exert its
effects. Most importantly, thepossiblecontribution ofFc-mediated processes needed
to be considered. These processes include lysis of cells by direct activation of the
complement pathway, and/or removal by macrophages activated through their Fc
receptors. The use of F(ab')2 fragments would exclude these possibilities (27). The
possible contribution ofCD8 multivalent crosslinking can alsobe obviated by using
F(ab')2 fragments, which can only form divalent interactions with the CD8 mole-
cule. Most importantly, the anti-CD8 F(ab')2 fragments used did not cause deple-
tion of CD4-/CD8+ T cells when injected into adult mice in a short term acute
treatment protocol (data not shown; see also references 16 and 27).
In vivo pre- and postnatal treatment with F(ab')2 fragments (>98% purity as de-
termined by SDS-PAGE analysis) saturated and blocked the expression of CD8 on
thymocytes (data not shown). More significantly, treatment with anti-CD8 F(ab')2
fragments prevented the development ofCD4-/CD8+ T cells. Fig. 5 a shows a lack
ofCD8-a+ Tcells in HC thymi from treated mice. The specificity of this effect is
demonstrated bythe observationthatthe generation oftheothermajor Tcellsubsets,
i.e., CD4+/CD8- and CD4+/CD8+ cells (data not shown), are not affected (Fig. 5
a). The failure to generate CD8+ Tcells after blocking the expression ofCD8 can
also be demonstrated by using other markers: absence of CD5+/CD4- and
TCR+/CD4- T cells (Fig. 5, b and c) confirms the finding that the CD4-/CD8+ T
cellsfailtodevelopwhen CD8 isblocked, even undercircumstances whereFc-mediated
mechanisms can be ruled out.
Finally, inordertodistinguish between cytotoxic removal ordevelopmental blockade
ofCD4-/CD8+ cells, we took advantage ofthe existence oftwo allelic forms ofthe
CD8 molecule (33). BALB/c mice expressthe CD8.2 allele, whileC3H miceexpress
the CD8.1 allele (26), and in heterozygous (C3H x BALB/c)Fi mice, both alleles
are codominantly expressed(32, 33; datanot shown). Anti-CD8.2 treatment ofsuch
(C3H x BALB/c)F1 mice should block only the CD8.2 molecule, but leave the ex-
pression ofthe CD8.1 molecule intact. Indeed, anti-CD8.2 F(ab')2 mAb treatment
ofperinatal (C3H x BALB/c)F, mice saturated all CD8.2 molecules on CD8+ cells,
while the expression of CD8.1 molecules was not affected (data not shown). It can
therefore be predicted that, if interactions between CD8 and its ligand are a re-
quirement for development, the remaining CD8.1 molecules should fulfill these re-ZUNIGA-PFLi1CKER ET AL .
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FIGURE 5 . Two-parameter flow cytometry
analysis ofcell surface expression of(a)CD4
vs. CD8-0, (6)CD5 vs . CD4, or (c)CD4 vs .
TCR-a/,6 on thymocytes from HC-treated
control and anti-CD8-F(ab')2-treated groups.
Timed pregnant BALB/c mice and their
offspring were treated with 2.43 mAb . In-
traperitoneal injections of0.5mg were given
daily from day 16 ofpregnancyand continued
at 0.2mgfor 12 d after birth. 'fhymocytes were
analyzed on day 13 after birth . Control and
anti-CD8-treated mice were injected with 0.2
mg, i.p ., ofHC 2 d before analysis .
quirements . Indeed, the generation of CD4-/CD8' cells in CD8.1/CD8.2 hetero-
zygous mice wasmostly unaffected by anti-CD8.2 treatment(Fig. 6, a-c), in striking
contrast with the situation in CD8.2 homozygous mice, in which anti-CD8 .2 treat-
ment resulted in a complete lack of generation ofCD4-/CD8' T cells (Figs. 5 and
6). Most likely, the generation ofCD4-/CD8+ cells in the heterozygous mice results
from interactions between the unblocked CD8.1 allele and its ligand, which pro-
vides the necessary signals fordifferentiation . These results firmly eliminate the pos-
sibility that the absence ofCD4-/CD8' cells in the anti-CD8-treated homozygous
mice was due to direct cytotoxic depletion, since such elimination would also have
occurred in heterozygous mice . Additionally, these data imply that the failure to
generate CD4-/CD8' T cells was not a consequence of negative signals (39, 40),
nor over induction of positive signals (39-44), resulting from themAb engagement
of CD8 molecules on differentiating thymocytes .
Taken together, these data clearly indicate that the generation ofCD4-/CD8' T
cells is preventedwhen CD8 molcules are blocked during earlydevelopment . In het-
erozygous Ft mice, where only one of the two CD8 alleles is blocked, the genera-
tion of CD4-/CD8+ T cells proceeds undisturbed, while treatment with non-
depleting F(ab')2-anti-CD8 mAb does block the development ofCD4-/CD8+ T cells
in homozygous mice . These results demonstrate that the absence of CD4-/CD8'
T cells is not due to a depletion CD8' T cells, but rather is caused by a lack ofposi-
tive selection. This lack ofpositive selection is most likely attributable to an obstructed
CD8-MHC class I interaction, and is presumably occurring at the double-positive434
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FIGURE 6.
￿
Two-parameter flow cytometry analysis ofcell surface expression of(a)CD4 vs . CD8,
(b) CD4 vs . CD8-(3, or (c)CD4 vs. TCR-a/,3 on thymocytes from HC-treated BALB/c or (C3H x
BALB/c)FI control and anti-CD8-F(ab')z-treated groups . Timed pregnant BALB/c orC3H mice
(mated to BALB/c males) and their offspring, BALB/c or (C3H x BALB/c)FI, respectively, were
treated with 2.43 mAb . Intraperitoneal injections of0 .5 mgwere given daily from day 16 ofpreg-
nancy and continued at 0 .2 mg for 12 d after birth . Thymocytes were analyzed on day 13 after
birth . Control and anti-CD8-treated mice were injected with 0 .2 mg, i .p ., ofHC 2 d before anal-
ysis . In both treated groups, BALB/c and (C3H x BALB/c)F I , the same anti-CD8 .2 F(ab)2mAb
batch, schedule, and dosage was used .
transition stage, since the development ofCD4`/CD8' T cells is not affected (Figs .
1 and 2) .
Summary
Interactions between self-MHC molecules andT cells are necessary for the proper
development of mature T cells, in part due to an absolute requirement for self-
MHCTCR interactions . Recently, we showed that C134-mediated interactions also
participate in shaping the T cell repertoire during thymic maturation . We now ex-
amine the possible role of the CD8 molecule during in vivo T cell development .
Our results demonstrate that perinatal thymi treated with intact anti-CD8 mAb
fail to generate CD8 single-positive T cells, while the generation of the other main
phenotypes remains unchanged . Most importantly, the use of F(ab')2 anti-CD8
mAb fragments gave identical results, i.e., lack of generation of CD4 -/CD8+ cells,
with no effect on the generation of CD4+/CD8` . Furthermore, selective blocking
of one CD8 allele with F(ab')2 mAbs in F1 mice expressing both CD8 alleles did
not interfere with the development ofCD4 -/CD8+ cells, demonstrating that the ab-sence of CD8' T cells in homozygous mice is not due to depletion, but rather is
caused by a lack of positive selection. This is most likely attributable to a deficient
CD8-MHC class I interaction. Our findings strongly advocate that CD8 molecules
are vital to the selection process that leads to the development ofmature single-positive
CD8 T cells.
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